AbbVie Inc. vs Target Corporation: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and Target Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating Target Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and Target Corporation is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against $104.8B for Target Corporation, while their respective market capitalizations stand at $451.5B and $63.1B. AbbVie Inc. is headquartered in United States and Target Corporation operates from United States, and those different home markets shape how each company competes.

AbbVie Inc.: AbbVie began as the separated pharmaceutical arm of Abbott Laboratories and became one of the world's largest biopharma companies by using Humira cash flow to build a broader portfolio. The company now presents itself as a diversified specialty-medicine platform rather than a single-product story.

Target Corporation: Target is a retailer whose value comes from making mass retail feel curated. The business is strongest when stores, digital channels, owned brands and fulfillment services reinforce one another.

AbbVie Inc. and Target Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and Target Corporation.

AbbVie Inc. business model: AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.

Target Corporation business model: Target's model combines large-format stores, digital commerce, store-based fulfillment, owned brands, loyalty, same-day services and retail media. Stores are both shopping destinations and local fulfillment nodes.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of Target Corporation.

AbbVie Inc. competitive advantage: AbbVie's advantage comes from deep immunology scale, specialist sales relationships, strong cash flow, global clinical and regulatory capabilities, and a portfolio led by Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Elahere.

Target Corporation competitive advantage: Target's advantage is the mix of curated merchandise, owned brands, convenient stores, same-day fulfillment and a brand position between discount utility and design-led retail.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and Target Corporation each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.

Target Corporation growth strategy: Target is focusing on merchandising authority, guest experience, technology acceleration, team and community strength, stores-as-hubs, same-day fulfillment, retail media and owned-brand renewal.

A closer look at the financial trajectory of AbbVie Inc. and Target Corporation rounds out the comparison.

AbbVie Inc.: AbbVie generated $61.160 billion in FY2025 net revenue, up 8.6% on a reported basis, with immunology contributing $30.406 billion. Q1 2026 revenue reached $15.002 billion, showing continued growth after the Humira patent cliff as Skyrizi and Rinvoq scaled.

Target Corporation: Target reported FY2025 revenue of $104.780B and net income of $3.705B. Q1 FY2026 net sales increased 6.7%, with comparable sales up 5.6% and EPS of $1.71.